Stock listing

OTC:BCLI Brainstorm Cell Therapeutics Inc. Stock

Follow Brainstorm Cell Therapeutics Inc. into a list and get an email when it puts out news.

Share price · OTC:BCLI

$0.753 USD -0.099 (-11.6%)

Close on Nov 20, 2026

Past year +17.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.753 – $0.810 USDNov 20, 2026
Volume
7,775 sharesNov 20, 2026
Market cap
$8.31M USDAt the close on Nov 20, 2026 · price × 11.03M shares outstanding
52-week range
$0.460 – $1.690 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$15,846 USDMedian day 11,483 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Brainstorm Cell Therapeutics Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:BCLI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.753-0.099-11.6%$0.810$0.810$0.7537,775
$0.852-0.029-3.3%$0.840$0.852$0.8402,504
$0.881-0.019-2.1%$0.960$0.998$0.88162,843
$0.900-0.090-9.1%$0.950$0.950$0.8913,850
$0.9900.0000.0%$0.990$1.000$0.97036,289
$0.990+0.035+3.7%$0.990$1.020$0.95039,634
$0.955-0.018-1.8%$0.973$0.990$0.87611,483
$0.973+0.024+2.5%$0.965$0.989$0.86415,609
$0.949+0.049+5.4%$0.830$0.949$0.83019,120
$0.900+0.040+4.7%$0.932$0.932$0.8024,045
$0.860+0.034+4.1%$0.811$0.860$0.70014,703
$0.8260.0000.0%$0.826$0.826$0.8111,878
$0.826+0.0000.0%$0.850$0.850$0.82610,252
$0.826-0.034-4.0%$0.828$0.828$0.811367
$0.860-0.049-5.3%$0.870$0.943$0.8563,476
$0.909+0.109+13.6%$0.800$0.943$0.80067,566
$0.8000.0000.0%$0.753$0.800$0.7534,721
$0.800+0.028+3.6%$0.800$0.800$0.7532,566
$0.772-0.048-5.8%$0.788$0.803$0.7656,538
$0.820+0.040+5.1%$0.800$0.830$0.75028,900
$0.780+0.010+1.3%$0.750$0.830$0.7509,500
$0.770-0.030-3.8%$0.750$0.830$0.7503,200
$0.800+0.030+3.9%$0.810$0.830$0.75018,100
$0.770-0.010-1.3%$0.830$0.830$0.7706,800
$0.780-0.020-2.5%$0.840$0.840$0.7807,400
$0.800-0.040-4.8%$0.840$0.840$0.8002,500
$0.840+0.010+1.2%$0.770$0.840$0.77021,100
$0.830-0.020-2.4%$0.850$0.850$0.77024,400
$0.850-0.100-10.5%$0.870$0.940$0.85012,800
$0.950+0.040+4.4%$0.930$0.960$0.88016,400
$0.910+0.010+1.1%$0.890$0.960$0.890700
$0.900-0.130-12.6%$0.960$0.960$0.9006,300
$1.030-0.020-1.9%$0.950$1.030$0.950900
$1.050+0.120+12.9%$1.000$1.050$0.92011,700
$0.930-0.070-7.0%$0.950$1.030$0.90016,600
$1.000+0.050+5.3%$0.940$1.080$0.92017,400
$0.950+0.030+3.3%$0.880$0.950$0.8807,700
$0.920-0.020-2.1%$0.920$0.920$0.920900
$0.940-0.030-3.1%$0.910$0.970$0.9101,400
$0.970+0.020+2.1%$0.980$0.980$0.96020,600
$0.950+0.080+9.2%$0.990$1.080$0.92019,000
$0.870-0.070-7.4%$0.830$0.990$0.8301,700
$0.940+0.070+8.0%$0.870$0.940$0.8702,200
$0.870-0.030-3.3%$0.870$0.900$0.85017,700
$0.900-0.080-8.2%$1.000$1.000$0.85026,800
$0.9800.0000.0%$0.930$1.030$0.9208,400
$0.980-0.060-5.8%$0.970$1.010$0.92032,900
$1.040-0.020-1.9%$1.060$1.080$0.9607,600
$1.060-0.020-1.9%$1.060$1.070$1.0601,800
$1.080+0.050+4.9%$1.060$1.080$1.02042,900
$1.030+0.030+3.0%$1.000$1.070$1.00017,900
$1.000+0.010+1.0%$0.980$1.060$0.9806,900
$0.990-0.060-5.7%$1.000$1.050$0.9806,900
$1.050-0.020-1.9%$1.060$1.060$1.0307,200
$1.070-0.180-14.4%$1.260$1.340$1.05042,391
$1.250+0.080+6.8%$1.180$1.300$1.13019,600
$1.170+0.100+9.3%$1.080$1.190$1.0303,700
$1.070-0.050-4.5%$1.070$1.090$0.98023,400
$1.120-0.040-3.4%$1.150$1.190$1.0703,600
$1.160-0.040-3.3%$1.200$1.220$1.11022,100
$1.200+0.200+20.0%$0.990$1.270$0.99048,300
$1.0000.0000.0%$1.000$1.000$0.99016,000
$1.000+0.020+2.0%$0.980$1.030$0.90023,900
$0.980-0.080-7.5%$1.110$1.130$0.90051,500
$1.060-0.160-13.1%$1.210$1.230$1.00056,500

Splits

3 splits since 2003 · OTC:BCLI · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-15Consolidation
2-for-1Split
Ticker
OTC:BCLI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Brainstorm Cell Therapeutics Inc. news

Brainstorm Cell Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 20, 2026 · oldest 2026
Calls
19 calls with a replay · 19 with a transcript · latest Aug 14, 2025
Decks
29 decks · latest May 8, 2025

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$10.08M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.40

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Brainstorm Cell Therapeutics Inc. · OTC:BCLIUS$8.31MUS$10.08Mn/an/an/an/an/an/a0.40
BioVie Inc. · NASDAQ:BIVIUS$8.58MUS$1.10Mn/an/an/a1.3×n/a0.0×1.84
Vyome Holdings, Inc. · NASDAQ:HINDUS$8.42MUS$1.82Mn/a11.9×n/a1.3×n/a0.1×1.34
CRISM Therapeutics Corporation · LSE:CRTXUS$8.34MUS$5.37Mn/a17.8×n/a2.5×−823.8%0.0×n/a
Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTMUS$8.29M−US$3.20Mn/an/an/a0.7×n/a0.1×1.05
Moleculin Biotech, Inc. · NASDAQ:MBRXUS$8.22MUS$1.04Mn/an/an/a0.6×n/a0.0×0.42
IN8bio, Inc. · NASDAQ:INABUS$8.19M−US$3.03Mn/an/an/a0.6×n/a0.2×1.25
Intensity Therapeutics, Inc. · NASDAQ:INTSUS$8.19M−US$220,086n/an/an/a1.1×n/a0.0×1.30
Palatin Technologies, Inc. · AMEX:PTNUS$8.16MUS$4.58Mn/a12.7×n/a4.0×n/a0.1×0.61
Dare Bioscience, Inc. · NASDAQ:DAREUS$8.01M−US$2.65Mn/a−1.9×n/a3.4×−749.8%0.4×1.34
Cellectar Biosciences, Inc. · NASDAQ:CLRBUS$8.00M−US$15.05Mn/an/an/a0.4×n/a0.1×1.71
Median of the othersUS$8.20MUS$408,09012.3×1.2×−786.8%0.1×1.30

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
17.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.91 · 1 analyst

Team and board

Officers

OfficerRole
Chaim LebovitsPresident, Chief Executive Officer
Alla PatlisInterim Chief Financial Officer
Haro HartounianExecutive Vice President, Chief Operating Officer
Mary Kay TurnerSenior Vice President, Patient Advocacy and Government Affairs
Netta Blondheim-ShragaSenior Vice President, Research and Development
Yossef LevyVice President, Cell Production
Peter J. PittsExecutive Chairman

Board

DirectorRole
Peter J. PittsExecutive Chairman
Anthony PolverinoDirector
Irit ArbelDirector
Menghis BairuDirector
Nir NaorDirector
Stacy LindborgDirector
Uri YablonkaDirector

Events

Calls

CallWhenStatus
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2025 Earnings CallThu, Aug 14, 2025 · 8:30 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2025 Earnings CallMon, May 19, 2025 · 8:30 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2024 Earnings CallMon, Mar 31, 2025 · 8:30 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2024 Earnings CallWed, Aug 14, 2024 · 8:30 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2023 Earnings CallTue, Nov 14, 2023 · 8:30 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2023 Earnings CallMon, Aug 14, 2023 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2023 Earnings CallMon, May 15, 2023 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2022 Earnings CallThu, Mar 30, 2023 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2022 Earnings CallMon, Nov 14, 2022 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2022 Earnings CallMon, Aug 15, 2022 · 8:00 AM ETReplay
All 19 calls
CallWhenStatus
Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2022 Earnings CallMon, May 16, 2022 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2021 Earnings CallMon, Mar 28, 2022 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2021 Earnings CallMon, Nov 15, 2021 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2021 Earnings CallWed, Aug 04, 2021 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2021 Earnings CallSun, Apr 25, 2021 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q4 2020 Earnings CallWed, Feb 03, 2021 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q3 2020 Earnings CallThu, Oct 15, 2020 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q2 2020 Earnings CallWed, Aug 05, 2020 · 8:00 AM ETReplay
Brainstorm Cell Therapeutics (OTC:BCLI) Q1 2020 Earnings CallThu, May 07, 2020 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 17, 2026−5.3%
Q2 2026Aug 17, 2026+42.4%
Q1 2026May 15, 2026 · After close0.0%
Q3 2025Nov 14, 2025 · After close+11.5%
Q2 2025Aug 14, 2025 · Before open−9.1%
Q1 2025May 15, 2025 · After close+13.8%
Q4 2024Mar 31, 2025 · Before open+5.9%
Q3 2024Nov 14, 2024 · After close+7.1%
Q2 2024Aug 14, 2024 · Before open−3.1%
Q1 2024Apr 1, 2024 · Before open+32.1%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 14, 2023 · Before open0.0%
Q2 2023Aug 14, 2023 · Before open+3.1%
Q1 2023May 15, 2023 · Before open0.0%
Q4 2022Mar 30, 2023 · Before open+2.5%
Q3 2022Nov 14, 2022 · Before open+7.9%
Q2 2022Aug 15, 2022 · Before open−1.4%
Q1 2022May 16, 2022 · Before open+4.8%
Q4 2021Mar 28, 2022 · Before open−4.4%
Quarter to Sep 30, 2021Nov 15, 2021 · Before open+2.4%
Quarter to Jun 30, 2021Aug 5, 2021 · Before open+4.5%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (May 2025)Technical8 slidesMay 8, 2025
Investor Presentation (October 2024)Investor deck29 slidesOctober 2024
Investor Presentation (2024)Investor deck29 slides2024
Technical Presentation (November 2023)Technical14 slidesNov 17, 2023
13th Annual California ALS Research Summit 2023Conference18 slidesJan 20, 2023
Biotech Showcase 2023Conference17 slidesJanuary 2023
ALS ONE, Industry Presentations (October 2022)Conference15 slidesOct 7, 2022
32nd International Symposia on ALS/MND 2021Conference19 slidesDecember 2021
2021 ALS One Research SymposiumConference15 slidesNov 30, 2021
37th Congress of ECTRIMS 2021Conference14 slidesOctober 2021
All 29 decks
DeckKindSlidesDate
12th Annual California ALS Research Summit (January 2021)Conference17 slidesJan 27, 2021
Investor Presentation (August 2020)Investor deck38 slidesAugust 2020
Technical Presentation (July 2020)Technical35 slidesJul 8, 2020
Conference Presentation (February 2020)Conference23 slidesFebruary 2020
Investor Presentation (January 2020)Investor deck17 slidesJanuary 2020
Dawson James Securities 5th Annual Small Cap Growth Conference (October 2019)Conference18 slidesOctober 2019
Investor Presentation (May 2019)Investor deck32 slidesMay 26, 2019
Investor Presentation (February 2019)Investor deck22 slidesFebruary 2019
ALS Research Forum January 24, 2019Conference21 slidesJan 24, 2019
Investor Presentation (November 2018)Investor deck20 slidesNovember 2018
Investor Presentation (September 2018)Investor deck16 slidesSeptember 2018
Cell Series UK 2019 ConferenceConference29 slidesMar 22, 2018
Corporate Update (March 2018)Corporate update20 slidesMar 8, 2018
Investor Presentation (February 2018)Investor deck21 slidesFebruary 2018
Investor Presentation (January 2018)Investor deck20 slidesJanuary 2018
Investor Day (2018)Investor day6 slides2018
Investor Presentation (August 2017)Investor deck19 slidesAugust 2017
Technical Presentation (December 2016)Technical23 slidesDec 9, 2016
Technical Presentation (July 2016)Technical17 slidesJul 18, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue703.0K849.0K0000-366.0K000
Cost of revenue240.0K265.0K285.0K260.0K219.0K366.0K110.0K85.0K77.0K
Gross profit-240.0K-265.0K-285.0K-260.0K-219.0K-732.0K-110.0K-85.0K-77.0K
Research and development4.17M4.65M10.7M14.0M15.2M22.3M17.2M8.29M977.0K2.25M
Selling, general and administrative5.78M7.04M10.7M10.9M9.30M9.36M5.80M5.77M4.02M2.83M
Operating income-9.95M-11.7M-21.4M-24.8M-24.5M-31.7M-23.0M-14.1M-5.00M-5.08M
Depreciation and amortization199.0K240.0K265.0K285.0K260.0K219.0K164.0K110.0K85.0K77.0K
EBITDA-9.75M-11.5M-21.2M-24.5M-24.3M-31.5M-22.8M-14.0M-4.91M-5.01M
Interest expense77.0K545.0K82.0K127.0K252.0K115.0K47.0K101.0K
Income before tax-10.3M-11.6M-17.2M-24.3M-24.5M-31.8M-23.3M-13.9M-4.95M-4.98M
Income tax11.6M-545.0K-82.0K127.0K252.0K-115.0K00
Net income-10.3M-11.6M-17.2M-24.3M-24.5M-31.8M-23.3M-13.9M-4.95M-4.98M
Earnings per share, basic-1.11-2.31-6.00-0.66-0.68-1.07-1.06-0.70-0.26-0.27
Earnings per share, diluted-1.11-2.31-6.00-0.66-0.68-1.07-1.06-0.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents29.0K187.0K1.30M772.0K18.9M37.8M536.0K942.0K2.48M547.0K
Short-term investments02.21M3.24M4.11M33.0K6.12M5.27M9.44M
Receivables86.0K63.0K51.0K91.0K86.0K304.0K2.36M2.01M672.0K306.0K
Inventory-51.0K00
Current assets307.0K385.0K1.90M3.11M23.3M43.2M3.36M10.3M9.62M10.4M
Property, plant and equipment235.0K434.0K686.0K933.0K1.19M1.12M960.0K651.0K392.0K297.0K
Goodwill00
Total assets1.02M1.83M4.21M8.45M29.3M51.3M6.53M11.2M11.4M10.8M
Accounts payable7.07M6.08M4.95M6.22M3.70M5.42M14.7M4.55M1.42M345.0K
Current liabilities11.0M8.98M7.80M8.80M6.32M11.2M17.7M6.21M5.54M864.0K
Long-term debt00
Total debt208.0K720.0K1.27M4.09M5.08M7.22M2.37M
Total liabilities11.0M9.60M9.07M11.5M9.94M15.8M18.8M6.21M5.54M864.0K
Shareholders' equity-9.98M-7.76M-4.86M-3.02M19.3M35.5M-12.2M5.02M5.88M9.90M
Shares outstanding11.0M6.14M4.03M36.7M36.4M35.2M23.2M20.8M19.0M18.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-6.97M-9.09M-20.5M-19.3M-26.3M-35.2M-11.2M-12.4M-2.36M-5.86M
Capital spending00-18.0K-29.0K-330.0K-378.0K-473.0K-369.0K-180.0K-103.0K
Free cash flow-6.97M-9.09M-20.5M-19.3M-26.6M-35.6M-11.7M-12.8M-2.54M-5.96M
Cash from investing12.0K2.19M998.0K323.0K-4.45M5.62M-1.22M3.99M5.98M
Cash from financing6.88M7.97M19.0M238.0K6.97M76.9M5.22M12.1M314.0K0
Dividends paid00
Share buybacks5.00K-116.0K3.16M12.1M314.0K0
Change in cash-95.0K-1.11M713.0K-18.1M-19.0M37.3M-406.0K-1.54M1.94M119.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
8-K · Current reportJul 30, 2026Management or board changeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 3, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
CORRESP · Letter to the SECJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
8-K · Current reportMay 28, 2026Management or board changeSEC
UPLOAD · Letter from the SECMay 27, 2026Other filingsSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 20, 2026Offer documentSEC
S-1 · Registration statementMay 20, 2026Offer documentSEC
8-K · Current reportMay 15, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportFeb 27, 2026Material contractSEC
8-K · Current reportFeb 13, 2026Material contractSEC
8-K · Current reportJan 9, 2026Material contractSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
8-K · Current reportNov 6, 2025Material contractSEC
25-NSEOct 9, 2025Other filingsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
RW · Request to withdraw a registrationJul 22, 2025Other filingsSEC
8-K · Current reportJul 17, 2025Current reportSEC
S-8 · Registration statement for employee plansJul 3, 2025Offer documentSEC
S-3 · Registration statementJun 25, 2025Offer documentSEC
8-K · Current reportJun 25, 2025Management or board changeSEC
8-K · Current reportJun 16, 2025Current reportSEC
8-K · Current reportMay 19, 2025Current reportSEC
ARS · Annual report to shareholdersMay 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialMay 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 16, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementMay 6, 2025Meeting noticeSEC
8-K · Current reportApr 21, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportMar 31, 2025Material contractSEC
8-K · Current reportMar 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 21, 2025Current reportSEC
8-K · Current reportJan 15, 2025Current reportSEC
4 · Change in ownershipJan 7, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedJan 7, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
8-K · Current reportOct 30, 2024Current reportSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
8-K · Current reportOct 1, 2024Current reportSEC
8-K · Current reportOct 1, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveSep 30, 2024Other filingsSEC
8-K · Current reportSep 26, 2024Current reportSEC
CORRESP · Letter to the SECSep 26, 2024Other filingsSEC
CORRESP · Letter to the SECSep 24, 2024Other filingsSEC
S-3/A · Registration statement, amendedSep 24, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 20, 2024Other filingsSEC
S-3 · Registration statementSep 17, 2024Offer documentSEC
8-K · Current reportSep 16, 2024Management or board changeSEC
EFFECT · Notice that a registration is effectiveSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 4, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 3, 2024Other filingsSEC
S-3 · Registration statementAug 28, 2024Offer documentSEC
ARS · Annual report to shareholdersAug 16, 2024Annual reportSEC
DEF 14A · Proxy statementAug 16, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
PRER14AAug 6, 2024Other filingsSEC
PRE 14A · Preliminary proxy statementAug 5, 2024Meeting noticeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
4/A · Change in ownership, amendedJul 31, 2024Insider tradeSEC
8-K · Current reportJul 30, 2024Current reportSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
8-K · Current reportJul 19, 2024Current reportSEC
424B5 · ProspectusJun 28, 2024Offer documentSEC
8-K · Current reportJun 28, 2024Material contractSEC
424B5 · ProspectusJun 27, 2024Offer documentSEC
8-K · Current reportJun 26, 2024Current reportSEC
4 · Change in ownershipJun 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 25, 2024Insider tradeSEC
8-K · Current reportJun 20, 2024Management or board changeSEC
8-K · Current reportJun 4, 2024Current reportSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 7, 2024Insider tradeSEC
4 · Change in ownershipMay 7, 2024Insider tradeSEC
8-K · Current reportMay 3, 2024Current reportSEC
4 · Change in ownershipApr 25, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 22, 2024Insider tradeSEC
4 · Change in ownershipApr 19, 2024Insider tradeSEC
8-K · Current reportApr 16, 2024Management or board changeSEC
8-K · Current reportApr 11, 2024Current reportSEC
8-K · Current reportApr 9, 2024Current reportSEC
424B5 · ProspectusApr 2, 2024Offer documentSEC
8-K · Current reportApr 2, 2024Material contractSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
8-K · Current reportApr 1, 2024ResultsSEC
4 · Change in ownershipMar 13, 2024Insider tradeSEC
4 · Change in ownershipMar 13, 2024Insider tradeSEC
4 · Change in ownershipMar 13, 2024Insider tradeSEC
4 · Change in ownershipMar 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
8-K · Current reportDec 20, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialNov 22, 2023Meeting noticeSEC
8-K · Current reportNov 22, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
8-K · Current reportNov 9, 2023Current reportSEC
DEF 14A · Proxy statementNov 8, 2023Meeting noticeSEC
8-K · Current reportNov 3, 2023Current reportSEC
8-K · Current reportOct 24, 2023Management or board changeSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
4 · Change in ownershipAug 7, 2023Insider tradeSEC
4 · Change in ownershipAug 4, 2023Insider tradeSEC
8-K · Current reportJul 19, 2023Material contractSEC
424B5 · ProspectusJul 19, 2023Offer documentSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 21, 2023Insider tradeSEC
8-K · Current reportJun 20, 2023Management or board changeSEC
8-K · Current reportJun 6, 2023Current reportSEC
8-K · Current reportMay 24, 2023Management or board changeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
4 · Change in ownershipMay 1, 2023Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2023Insider tradeSEC
4 · Change in ownershipApr 24, 2023Insider tradeSEC
4 · Change in ownershipApr 24, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedApr 5, 2023Big-stake noticeSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
8-K · Current reportMar 27, 2023Current reportSEC
8-K · Current reportJan 11, 2023Meeting outcomeSEC
8-K · Current reportJan 4, 2023Material contractSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
DEF 14A · Proxy statementDec 13, 2022Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 14, 2022ResultsSEC
8-K · Current reportOct 11, 2022Current reportSEC
8-K · Current reportSep 22, 2022Material contractSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 15, 2022ResultsSEC
10-Q · Quarterly reportMay 16, 2022Quarterly reportSEC
8-K · Current reportMay 16, 2022ResultsSEC
4 · Change in ownershipApr 8, 2022Insider tradeSEC
10-K · Annual reportMar 28, 2022Annual reportSEC
8-K · Current reportMar 28, 2022ResultsSEC
4 · Change in ownershipMar 14, 2022Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 4, 2022Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2022Insider tradeSEC
8-K · Current reportJan 28, 2022ResultsSEC
8-K · Current reportDec 17, 2021Management or board changeSEC
4 · Change in ownershipDec 17, 2021Insider tradeSEC
4 · Change in ownershipDec 17, 2021Insider tradeSEC
4 · Change in ownershipDec 17, 2021Insider tradeSEC
4 · Change in ownershipDec 17, 2021Insider tradeSEC
4 · Change in ownershipDec 17, 2021Insider tradeSEC
4 · Change in ownershipDec 10, 2021Insider tradeSEC
4 · Change in ownershipDec 10, 2021Insider tradeSEC
4 · Change in ownershipDec 10, 2021Insider tradeSEC

This page holds 200 of 952 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Brainstorm Cell Therapeutics Inc.’s releases · as of Sep 30, 2026

Common shares
11,034,775
Fully diluted
11,034,775

Fully diluted

LineSharesAs of
Common shares11,034,775Sep 30, 2026

Share count over time

CountShares
Nov 22, 202611,034,775
Sep 30, 202614,259,377

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jacob A Frenkel
Other companies: BXP, Inc. (Director · Feb 24, 2010 – May 31, 2018 · Past); Loews Corporation (Director · Nov 30, 2009 – May 8, 2019 · Past); American International Group, Inc. New (Vice Chairman · Jul 1, 2007 – Sep 1, 2009 · Past)
Director · Since at least Mar 30, 2020
Eyal Rubin
Other companies: Nasus Pharma Ltd. (Executive Vice President and Chief Financial Officer · Since at least Nov 20, 2025); Protalix BioTherapeutics, Inc. (de) (Sr. VP and CFO · Sep 22, 2019 – Sep 23, 2024 · Past)
CFO and Treasurer · Nov 20, 2017 – Nov 20, 2017 · Past
Stacy R. Lindborg
Other companies: Imunon, Inc. (President, Chief Executive Officer, and Board Director · Since at least Jun 4, 2021)
Director · Since at least Jun 1, 2020
Alla PatlisInterim Chief Financial Officer · Since at least May 13, 2015
Alon PinkasDirector · Apr 19, 2013 – Jun 22, 2016 · Past
Anthony PolverinoDirector · Since at least Jan 1, 2025
Arturo ArayaChief Commercial Officer · Feb 26, 2017 – Dec 24, 2019 · Past
Chaim LebovitsPresident, Chief Executive Officer · Since at least Sep 28, 2015
Haro HartounianExecutive Vice President, Chief Operating Officer · Since at least Nov 4, 2026
Ibrahim B DagherDirector · Since at least Apr 17, 2024
All 21 people
PersonSeat
Irit ArbelDirector · Since at least Jun 22, 2016
Kirk TaylorChief Medical Officer · May 1, 2023 – May 1, 2023 · Past
Mary Kay TurnerSenior Vice President, Patient Advocacy and Government Affairs · Since at least Nov 4, 2026
Menghis BairuDirector · Since at least Nov 4, 2026
Menghisteab BairuDirector · Since at least Feb 26, 2026
Moshe LionDirector · Jul 16, 2007 – Aug 31, 2009 · Past
Netta Blondheim-ShragaSenior Vice President, Research and Development · Since at least Nov 4, 2026
Nir NaorDirector · Since at least Nov 4, 2026
Peter J. PittsExecutive Chairman · Since at least Nov 4, 2026
Uri YablonkaDirector · Since at least Nov 4, 2026
Yossef LevyVice President, Cell Production · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Brainstorm Cell Therapeutics Inc.